Methods of purifying bispecific antibodies

Abstract

The invention relates to the purification of bispecific antibodies carrying a different specificity for each binding site of the immunoglobulin molecule from a mixture of monospecific antibodies. The bispecific antibodies are composed of a single heavy chain and two different light chains, one containing a Kappa constant domain and the other a Lambda constant domain. This invention in particular relates to the isolation of these bispecific antibodies from mixtures that contain monospecific antibodies having two Kappa light chains or portions thereof and monospecific antibodies having two Lambda light chains or portions thereof. The invention also provides the methods of efficiently purifying these bispecific antibodies.

What is claimed is: 
     
         1 . A method of purifying a bispecific antibody from a mixture of antibodies, the method comprising the steps of:
 (a) providing a mixed antibody composition that comprises (i) at least one bispecific antibody with a different specificity in each combining site and two copies of a single heavy chain polypeptide, a first light chain with a kappa constant region, and a second light chain with a lambda constant region (κλ-body); (ii) at least one monospecific antibody having two lambda light chains or portions thereof (λ mono-Ab); and (iii) at least one monospecific antibody having two kappa light chains or portions thereof (κ mono-Ab);   (b) providing a separation means;   (c) contacting the separation means with the mixed antibody composition under conditions that allow for differential binding to the separation means by the κλ-body as compared to the binding to the separation means by the κ mono-Ab and the λ mono-Ab; and   (d) eluting the κλ-body, the κ mono-Ab, and the λ mono-Ab from the separation means under conditions that allow for preferential detachment of the κλ-body from the separation means as compared to detachment of κ mono-Ab and of the λ mono-Ab from the separation means.   
     
     
         2 . The method of  claim 1 , wherein the separation means is a resin, a membrane, a magnetic bead, a particle or a monolith. 
     
     
         3 . The method of  claim 1 , wherein the binding conditions comprise a variation in pH level, salt level, or both pH level and salt level. 
     
     
         4 . The method of  claim 1 , wherein the elution conditions comprise a step variation in pH level, salt level, both pH level and salt level, Hofmeister ion level, both pH and Hofmeister ion level, buffer concentration, buffer composition, both buffer concentration and composition, and combinations thereof. 
     
     
         5 . The method of  claim 1 , wherein the separation means is a mixed mode chromatography resin. 
     
     
         6 . The method of  claim 5 , wherein the separation means is a TOYOPEARL® MX-Trp 650M resin. 
     
     
         7 . The method of  claim 4 , wherein the separation means is a mixed mode chromatography resin. 
     
     
         8 . The method of  claim 7 , wherein the separation means is a TOYOPEARL® MX-Trp 650M resin. 
     
     
         9 . The method of  claim 1 , wherein the separation means is a hydrophobic interaction chromatography resin. 
     
     
         10 . The method of  claim 9 , wherein the separation means is a TOYOPEARL® Butyl 600M resin. 
     
     
         11 . The method of  claim 4 , wherein the separation means is a hydrophobic interaction chromatography resin. 
     
     
         12 . The method of  claim 11 , wherein the separation means is a TOYOPEARL® Butyl 600M resin. 
     
     
         13 . The method of  claim 1 , wherein step (a) comprises performing affinity chromatography on a biological sample to provide the mixed antibody composition. 
     
     
         14 . The method of  claim 13 , wherein the biological sample is cell supernatant. 
     
     
         15 . The method of  claim 14 , wherein the cell is transfected with a κλ bispecific expression vector comprising one γ1 heavy chain cDNA sequence, one κ light chain cDNA sequence, and one λ cDNA sequence. 
     
     
         16 . The method of  claim 13 , wherein the affinity chromatography is Protein A chromatography. 
     
     
         17 . The method of  claim 13 , wherein the affinity chromatography is not Protein A chromatography. 
     
     
         18 . The method of  claim 13 , wherein the separation means comprises a combination of a hydrophobic interaction chromatography resin and a mixed mode chromatography resin. 
     
     
         19 . The method of  claim 18 , wherein the separation means comprises use of a hydrophobic interaction chromatography resin followed by use of a mixed mode chromatography resin. 
     
     
         20 . The method of  claim 19 , wherein the hydrophobic interaction chromatography resin comprises a TOYOPEARL® Butyl 600M resin, and wherein the mixed mode chromatography resin comprises a TOYOPEARL® MX-Trp 650M resin. 
     
     
         21 . The method of  claim 18 , wherein the separation means comprises use of a mixed mode chromatography resin followed by use of a hydrophobic interaction chromatography resin. 
     
     
         22 . The method of  claim 21 , wherein the mixed mode chromatography resin comprises a TOYOPEARL® MX-Trp 650M resin, and wherein the hydrophobic interaction chromatography resin comprises a TOYOPEARL® Butyl 600M resin.